Nektar Therapeutics (NASDAQ:NKTR) — Market Cap & Net Worth
Market Cap & Net Worth: Nektar Therapeutics (NKTR)
Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $2.38 Billion ($2.38 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5514 globally and #1820 in its home market, demonstrating a 1.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nektar Therapeutics's stock price $70.67 by its total outstanding shares 33742147 (33.74 Million). See capital reinvestment ratio of Nektar Therapeutics to understand how much of operating cash flow is reinvested back into capital assets.
Nektar Therapeutics Market Cap History: 2015 to 2026
Nektar Therapeutics's market capitalization history from 2015 to 2026. Data shows growth from $568.56 Million to $2.38 Billion (18.53% CAGR).
Index Memberships
Nektar Therapeutics is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.10% | #144 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #635 of 3165 |
Weight: Nektar Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nektar Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nektar Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
25.83x
Nektar Therapeutics's market cap is 25.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $414.02 Million | $165.44 Million | -$153.52 Million | 2.50x | N/A |
| 2017 | $2.02 Billion | $307.71 Million | -$96.69 Million | 6.55x | N/A |
| 2018 | $1.11 Billion | $1.19 Billion | $681.31 Million | 0.93x | 1.63x |
| 2019 | $728.32 Million | $114.62 Million | -$440.67 Million | 6.35x | N/A |
| 2020 | $573.62 Million | $152.91 Million | -$444.44 Million | 3.75x | N/A |
| 2021 | $455.86 Million | $101.91 Million | -$523.84 Million | 4.47x | N/A |
| 2022 | $76.26 Million | $92.06 Million | -$368.20 Million | 0.83x | N/A |
| 2023 | $19.06 Million | $90.12 Million | -$276.06 Million | 0.21x | N/A |
| 2024 | $31.38 Million | $98.43 Million | -$118.96 Million | 0.32x | N/A |
| 2025 | $1.43 Billion | $55.23 Million | -$164.08 Million | 25.83x | N/A |
Competitor Companies of NKTR by Market Capitalization
Companies near Nektar Therapeutics in the global market cap rankings as of August 3, 2026.
Key companies related to Nektar Therapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Nektar Therapeutics Historical Marketcap From 2015 to 2026
Between 2015 and today, Nektar Therapeutics's market cap moved from $568.56 Million to $ 2.38 Billion, with a yearly change of 18.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.38 Billion | +67.15% |
| 2025 | $1.43 Billion | +4446.24% |
| 2024 | $31.38 Million | +64.60% |
| 2023 | $19.06 Million | -75.00% |
| 2022 | $76.26 Million | -83.27% |
| 2021 | $455.86 Million | -20.53% |
| 2020 | $573.62 Million | -21.24% |
| 2019 | $728.32 Million | -34.33% |
| 2018 | $1.11 Billion | -44.96% |
| 2017 | $2.02 Billion | +386.72% |
| 2016 | $414.02 Million | -27.18% |
| 2015 | $568.56 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Nektar Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.38 Billion USD |
| MoneyControl | $2.38 Billion USD |
| MarketWatch | $2.38 Billion USD |
| marketcap.company | $2.38 Billion USD |
| Reuters | $2.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more